Please check the following:
- {{error.value}}
FREE membership
FREE membership
Join InvestSMART today
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
Please enter the 5 digit verification code sent to "{{user.DayPhone}}" Change number
We cannot send you a verification code via SMS to "{{user.DayPhone}}" Change number
{{ completedStep1 ? 'Start your free 15 day trial now' : content.trialHeading.replace('{0}', user.FirstName) }}
Please enter your mobile number and press send to receive a text message with a verification code.
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
Thank you
We have sent you an email with the details of your registration.
Purchase order
Sign up
OR
Sign up with
Login with
By continuing, you agree to our
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
Looks you are already a member. Please enter your password to proceed
OR
Sign up with
Login with
By continuing, you agree to our
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Log in
Your account has been locked.
Please contact our {{ isPMAUser ? 'Portfolio Services' : 'Customer Service' }} Team:
- Call 1300 880 160
OR
Sign up with
Login with
By continuing, you agree to our
Upgrade Today
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
{{eventFunction.Name}}
{{eventFunction.EventTypeName}}
{{eventFunction.StartDate}}
{{eventFunction.EventTimings}}
{{eventFunction.VenueName}}
{{ t.Cost === 0 ? "FREE" : "$" + t.Cost.toFixed(2) }}
Quantity *
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
Check your inbox
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
Patrys Limited (ASX:PAB)
ALERT: Price-sensitive ASX Announcement for PAB
Current share price for PAB : $0.033 0 (0%)+
Announcement
Release
30 Jan 2026 8:17AM
Price at Release
$0.033
Full Release
Summary
Patrys Limited released its Quarterly Activities Report along with the Appendix 4C Quarterly Cash Flow report for the quarter ended 31 December 2025. During this period, Patrys announced the acquisition of Reliis Pty Ltd, marking a strategic expansion into CNS therapeutics with a proprietary injectable formulation of quetiapine, RLS-2201, aimed at treating delirium. This acquisition is expected to broaden Patrys' development portfolio with near-term clinical milestones. Furthermore, Patrys continued to advance its deoxymab platform, focusing on preclinical programs for immune-mediated inflammatory diseases. The company recorded net cash outflows from operating activities amounting to $674,000, offset by an R&D rebate, leaving a cash balance of $1.9 million at the end of the quarter.
Key Points
- Patrys Limited acquired Reliis Pty Ltd, expanding into CNS therapeutics.
- RLS-2201 is an injectable formulation of quetiapine for delirium treatment.
- The acquisition introduces near-term clinical and regulatory milestones.
- Continued advancement of the deoxymab platform for inflammatory diseases.
- Net cash outflows from operating activities were $674,000 with a $1.9M cash balance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
